Skip to main content
. 2018 Jul 24;11(4):284–290. doi: 10.1007/s12254-018-0422-0

Table 2.

Overview of updated survival data of the KEYNOTE-052 and IMvigor 210 (cohort 1) trial in comparison to results of the EORTC 30986

KEYNOTE-052
[29], Abstract #4524
IMvigor210 (Cohort 1)
[28], Abstract #4523
EORTC 30986
[25], Gemcitabine/carboplatin
Study population (n) 370 119 238
ORR (%) 28.9 24 36
CR Rate (%) 8.1 8 6.1
Median OS (months) 11.5 16.3 9.3
1-Year OS rate (%) 47.5 58 37
2-Year OS rate (%) 41 18

ORR objective response rate, OS overall survival, CR complete response